The key advantage of VNPP433-3β is its ability to target multiple signaling and metabolic pathways (AR, eIF4E, Mnk1/2, inhibition of 5′cap-dependent mRNA translation, etc.)that play crucial roles in the development and progression of PCa. The gene discussed is MKNK1; the disease is posterior cortical atrophy.